Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Ibuprofen 100 mg/5 mL in 50 mL, 100 mL, 200 mL Suspension, oral Whitehall-Robins, Richmond, Virginia, United States of America and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Act-3 Alteplase (plasminogen activator) 10 mg, 20 mg, 50 mg and diluent Injection, powder, glass vial; diluent, ampoule Dr Karl Thomae GmbH., Biberach, Biberach an der Riss, Germany Actilyse Ipratropium bromide monohydrate 0.52 mg equivalent to 0.5 mg ipratropium bromide, salbutamol sulphate 3.01 mg equivalent to 2.5 mg salbutamol in 2.5 mL Solution, inhaled Boehringer Ingelheim Limited, Bracknell, Berkshire, England Combivent Respules Etoposide phosphate 113.6 mg equivalent to 100 mg etoposide Injection, powder, glass vial Bristol-Caribbean Inc., Mayaguez, Puerto Rico Etopophos Cetylpyridinium chloride 1.5 mg Lozenge Barratts Pharmaceuticals Pty Limited, Blacktown, New South Wales, Australia Lemsip Cisapride 5 mg, 10 mg Tablets Janssen Pharmaceutic nv., Beerse, Belgium Prepulsid Cisapride 20 mg Tablet Janssen Pharmaceutic nv., Beerse, Belgium Prepulsid Forte Dated this 6th day of January 1997. KAREN O. POUTASSI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.